Rebamipide and mosapride enhance pilocarpine-induced salivation

Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Yosuke Sasaki, Kazuo Hike, Hiroshi Muto, Masaki Sanaka, Nagato Shimada, Hitoshi Nakajima, Motonobu Sugimoto.
Department of General Medicine and Emergency Care, Toho University School of Medicine, Tokyo, Japan.

**Background:** During esophageal acid clearance, salivation plays an important role in defending the esophageal mucosa. Mosapride, an agent used in chronic, long-term therapy of gastro-esophageal reflux disease (GERD) was regarded as mediating its efficacy through prokinetic properties. Rebamipide is also widely used as an anti-gastritis and anti-ulcer agent in GERD patients with chronic gastritis. The aim of this study is to investigate the effects of rebamipide, mosapride, and risperidone on the salivation induced by pilocarpine.

**Materials and Methods:** The experiments were conducted on 4-week male SD rats (120-150g). The salivation was induced by intraperitoneally administrated pilocarpine and saliva was collected using preweighted small cotton balls inserted into the animal's mouth every 30 min for 180 min. Thirteen minutes before intraperitoneal administration of pilocarpine, rebamipide, mosapride, and risperidone were administered intraduodenally. Control rats were conducted by intraperitoneal administration of saline and intraduodenal administration of 0.5% methylcellulose solution.

**Results:** The saliva weight at 0-30 min was significantly (p<0.01) increased after administration of pilocarpine, compared to control rats. An additional administration of mosapride and rebamipide increased the saliva weight at 0-30 min. The total volume of saliva for 150 min after administration of pilocarpine was the highest after preadministration of rebamipide, followed by mosapride, and risperidone.

**Conclusions:** Increase in salivation produced by i.p. pilocarpine was enhanced by preadministration of rebamipide and mosapride. (Urita Y, Watanabe T, Maeda T, Sasaki Y, Hike K, Muto H, Sanaka M, Shimada N, Nakajima H, Sugimoto M. North Am J Med Sci 2009; 1: 121-124).

**Keywords:** pilocarpine- induced salivation; mosapride; rebamipide.

**Introduction**

Since exposure of the distal esophagus to acid is implicated in elicitation of both symptoms and mucosal damage, the importance of esophageal clearance is generally recognized [1, 2]. During esophageal acid clearance, salivation plays an important role in defending the esophageal mucosa [3, 4]. It is conside red that systemically administered pilocarpine induces the salivary secretion. Additionally, it has been reported that intracerebroventricular injection of pilocarpine also induces salivary secretion in anesthetized rats [5, 6]. Takakura et al [7] also demonstrated that the pretreatment with intracerebroventricular injection of atropine inhibited the salivation induced by intraperitoneally administrated pilocarpine, suggesting that the salivary secretion elicited by systemically administered pilocarpine is mediated through the central nervous system as well as through the salivary glands.

Many studies suggest that proton pump inhibitors (PPIs) are the most effective medical therapy to control gastro-esophageal reflux disease (GERD) symptoms and heal esophagitis [8, 9]. PPIs are the major acid-suppressing drugs used for the treatment of GERD and have better characteristics for the long-term treatment of GERD, because they have a long-lasting, strong effect of raising intragastric pH and have no tachyphylaxis/tolerance phenomena on repeated dosing. However, PPI failure has become more prevalent with the increasing use of PPI as the first-line agent in the treatment of GERD [10]. On the other hand, laryngopharyngeal reflux (LPR) is a major cause of laryngeal inflammation and presents with a constellation of symptoms different from classic gastroesophageal reflux disease. Although LPR is frequently treated with empiric PPIs, most patients require more aggressive and prolonged treatment to achieve regression of symptoms [11].

Mosapride, which has been known to have both a 5-HT4 receptor agonistic and a 5-HT3 antagonist action and to be an agent used in chronic, long-term therapy of GERD was regarded as mediating its efficacy through prokinetic properties. Rebamipide is also widely used as an anti-gastritis and anti-ulcer agent in GERD patients with chronic gastritis. However, these other effects of the study drugs would make these agents even more attractive in the treatment of patients with GERD. Therefore, in the present study, we investigated the effects of rebamipide, mosapride, and risperidone on the salivation induced by pilocarpine.
Material & Methods

The experiments were conducted on 4-week male SD rats (120-150g). They were maintained under standard animal-housing conditions and had access to water and laboratory pellets except during the experimental period. After a 24-h fast, under urethane anesthesia, a tracheal catheter was inserted after in cising the trachea to secure the airway.

Laboratory diet pellets were removed one hour before the measurement of saliva secretion. The salivation was induced by intraperitoneally administered pilocarpine (0.5 mg/kg of body weight), and saliva was collected using preweighted small cotton balls inserted into the animal's mouth every 30 min for 180 min. On the day of the experiments, rats were sedated with urethane (1mg/g) intraperitoneally, and kept in lateral decubitus. The cotton ball, 0.5 cm in diameter, was prepared and weighed in an analytic electronic scale. The first cotton ball was inserted under the rat’s tongue. The salivary excretion is determined through the difference in weight of the cotton ball before and after collection. The procedure of salivation was done at 30-min intervals after pilocarpine was administered intraperitoneally. Thirteen minutes before intraperitoneal administration of pilocarpine, rebamipide (10mg/kg), mosapride (1mg/kg), and risperidone (1mg/kg) were administered intraduodenally using a metallic tube. Control rats were conducted by intraperitoneal administration of saline (1 mL/kg) and intraduodenal administration of 0.5 % methylcellulose solution. Each group consisted of 15 rats.

Results

Figure 1 shows the time-course changes in salivary secretion in four stimulated groups and unstimulated control group. The salivary secretion was stimulated with intraperitoneal administration of pilocarpine alone (pilocarpine group), pilocarpine and risperidone (risperidone group), pilocarpine and mosapride (mosapride group), and pilocarpine and rebamipide (rebamipide group). Saliva secretion reached a peak at 0-30 min and decreased gradually to the baseline at 150 min. The saliva weight at 0-30 min was significantly (p<0.01) increased after administration of pilocarpine, compared to control rats. Contrary to the expectation, the saliva weight at 0-30 min was significantly (p<0.01) lower after additional intraduodenal administration of risperidone than after intraperitoneal administration of pilocarpine alone. An additional administration of mosapride and rebamipide increased the saliva weight at 0-30 min, but the differences did not reach a statistical significance.

Figure 2 demonstrated changes in saliva weight percent of risperidone, mosapride, and rebamipide group versus pilocarpine group. Mosapride group exceeded rebamipide group in salivary secretion at 90-120 min and had the highest value at 120-150 min.

Fig. 1 The time-course changes in salivary secretion in four stimulated groups and unstimulated control group. Generally, saliva secretion reached a peak at 0-30 min and decreased gradually to the baseline at 150 min. The saliva weight at 0-30 min was significantly lower in risperidone group than in pilocarpine alone.

Fig. 2 Changes in mean salivary weight percent of risperidone, mosapride, and rebamipide group versus pilocarpine group. Mosapride group exceeded rebamipide group in salivary secretion at 90-120 min and had the highest value at 120-150 min.

Fig. 3 Total volume of saliva for 150 min in each group. Rebamipide group had a maximum of total salivary secretion, followed by Mosapride group, Pilocarpine group, and Risperidone group.

Total volume of saliva for 150 min after administration of pilocarpine was 192.2 +/- 29.6 mg without premedication, 148 +/- 22.2 mg with preadministration of risperidone, 225.3 +/- 26.7 mg with preadministration of mosapride, and 244.4 +/- 28.7 mg with preadministration of
rebamipide (Fig. 3). These differences (versus pilocarpine alone) did not reach the statistical significance. Fig.4 demonstrated the percent of saliva weight in risperidone, mosapride, and rebamipide group in comparison with pilocarpine group at 0-60 min, 60-120 min, and 0-150 min. Increase in saliv a volume after preadministration of rebamipide and mosapride is the maximum at 60-120 min (176.6% and 173.4%, respectively). In contrast, saliva secretion was reduced after p readministration of risperidone.

**Discussion**

The major salivary glands produce 90% of the approximately 1.5L of saliva per day. In the basal state, 70% of saliva is secreted by the submandibular and sublingual glands [12]. The various functions of saliva include mechanical cleansing of the oral cavity, contributing to oral homeostasis and dental health. The lubrication property of saliva depends on its contents of mucins forming a gel that coats the food and makes it more easily moved about in the mouth. Various kinds of enzymes are present in saliva, including amylase, lysozyme, sialoperoxidase, lingual lipase, ribonuclease, deoxyribonuclease, and kallikreins. Amylase is the major digestive enzyme and begins the digestion of starches. Lysozyme and sialoperoxidase provide important protective functions.

Xerostomia is the subjective feeling of a dry mouth, which is not necessarily linked with a significant reduction in salivary flow. Saliva secretion is vital for maintaining oral health and function; thus, complications arising from hyposalivation such as dental caries, difficulty in swallowing, speaking and chewing, and an increased incidence of oral infection. The prevalence of xerostomia is not usually possible to distinguish from xerostomia because the etiology of hyposalivation is not very different from that of xerostomia. The diagnosis of hyposalivation is made by means of saliva flow rate measurement, and for chewing stimulated whole saliva, a cut-off value of 0.5 mL/min has been suggested to represent pathological secretion [15]. Esophageal acid clearance mainly depends on esophageal peristalsis and gravity leaving only a minimal residue that sustains an acidic pH in the esophageal mucosa until it is neutralized by swallowed saliva [16]. Salivary flow, volume, clearance, and alterations in the salivary electrolytic composition can influence the protective capacity of the regional mucous membrane [17]. Thus, hyposalivation is associated with various diseases.

There are a variety of causes but the major ones are medication, especially tricyclic antidepressants and sympathomimetic drugs, head and neck irradiation, and autoimmune inflammatory diseases such as Sjogren’s syndrome, which targets exocrine glands in general [13].

Hyposalivation is not usually possible to distinguish from xerostomia because the etiology of hyposalivation is not very different from that of xerostomia. The diagnosis of hyposalivation is made by means of saliva flow rate measurement, and for chewing stimulated whole saliva, a cut-off value of 0.5 mL/min has been suggested to represent pathological secretion [15]. Esophageal acid clearance mainly depends on esophageal peristalsis and gravity leaving only a minimal residue that sustains an acidic pH in the esophageal mucosa until it is neutralized by swallowed saliva [16]. Salivary flow, volume, clearance, and alterations in the salivary electrolytic composition can influence the protective capacity of the regional mucous membrane [17]. Thus, hyposalivation is associated with various diseases.

The secretion of saliva can be induced by several pharmacological drugs that mimic the natural neurotransmitters particularly those of the parasympathetic nervous system. Acetylcholine rapidly elicits a large volume of watery saliva, particularly from the serous parotid glands. Pilocarpine, a presentative Dialogogue, is well known for its largely parasympathetic stimulation and reduces depression of salivary secretion in human [18]. Despite the increased salivary secretion after administration of pilocarpine, thirst in the mouth is also induced via the central nervous system [19]. Higher dosage of pilocarpine can result in not only increased salivary secretion but also increased water intake. This may raise serious problems when pilocarpine is used as a medication for xerostomia. In order to attenuate the side effects of pilocarpine, the other drugs taken together have been used in clinical practice.

Nizatidine, a histamine H2 receptor antagonist, has been reported to inhibit acetylcholine esterase, with a resultant increase in acetylcholine, in the cholinergic system [20]. Adach et al [21] reported increased salivary secretion and bicarbonate output by nizatidine. Mosapride is a novel prokinetic agent which seems to exert its action via a high affinity and specificity for 5-HT4 receptors. 5-HT4-mediated acetylcholine release from postganglionic neurons in the myenteric plexus has been suggested as an important mechanism behind the effects of prokinetic substances [22]. As expected, pilocarpine-induced salivation was enhanced by mosapride in the present study. On the other hand, contrary to our expectations, rebamipide also enhanced pilocarpine-induced salivation. Rebamipide is also widely used as an anti-gastritis and anti-ulcer agent in patients with chronic gastritis because it has oxygen radical scavenging effects and stimulates prostaglandin generation in the gastric mucosa [23]. Since the secretion of saliva is mainly in response to cholinergic nerve stimulation, we examined expression of dopamine 2 receptor (D2R) using immunohistochemistry in salivary
glands of rats. D2R was expressed more densely in rats with rebamipide than in those with mosapride and in controls (data not shown). It has been reported that D2Rs are localized to cholinergic nerve endings in the gastric myenteric plexus, and these presynaptic D2Rs mediate inhibition of acetylcholine release [24]. Therefore, antagonism of D2Rs results in an increase in acetylcholine release. Based on the fact that salivary secretion is regulated by parasympathetic nervous system and D2R are expressed in salivary glands of rats, D2R antagonists might be able to enhance the output of saliva.

Conclusions
Increase in salivary production induced by intraperitoneal administration of pilocarpine was enhanced by preadministration of rebamipide and mosapride. The stimulatory impact of these drugs on salivary secretion preadministration of rebamipide and mosapride. The administration of pilocarpine was enhanced by Increase in salivation produced by intraperitoneal administration of mosapride. The administration of pilocarpine was enhanced by pilocarpine-induced salivation. J Dent Res 2003; 82: 310, 284-288.

Conflict of Interest Disclosure
We hereby declare that there are not any potential conflicts of interest that are relevant to the manuscript.

References
1. Dodds WJ, Hogan WJ, Helm JF, Ent J. Pathogenesis of reflux esophagitis. Gastroenterology 1981; 81: 376-394.
2. Helm JF, Dodds WJ, Pele L, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984; 310, 284-288.
3. Kao CH, Ho YJ, Chang Lai SP, Ding H. Evidence for decreased salivary function in patients with reflux esophagitis. Digestion 1999; 60, 191-195.
4. Helm JF, Dodds WJ, Hogan WJ. Salivary response to esophageal acid in normal subjects and patients with reflux esophagitis. Gastroenterology 1987; 93, 1393-1397.
5. Moreira TS, Takakura AC, de Luca LA Jr, Renzi A, Menani JV. Inhibition of pilocarpine-induced salivation in rats by central noradrenaline. Arc Oral Biol 2002; 47: 429-434.
6. Zenri A, de Luca RA Jr, Menani JV. Lesions of the lateral hypothalamus impair pilocarpine-induced salivation in rats. Brain Res Bull 2002; 58: 455-459.
7. Takakura AC, Moreira TS, Laitano SC, de Luca LA Jr, Renzi A, Menani JV. Central muscarinic receptors signal pilocarpine-induced salivation. J Dent Res 2003; 82: 993-997.
8. Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenäs E, Lundberg K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-1311.
9. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive esophagitis. Am J Gastroenterol 1996; 91: 1749-1757.
10. Cheung TK, Wong BC. Proton pump inhibitor failure/resistance: proposed mechanisms and therapeutic algorithm. J Gastroenterol Hepatol 2006; 21 (Suppl): S119-124.
11. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294: 1534-1540.
12. Stuchell RN, Mandel ID. Salivary gland dysfunction and swallowing disorders. Otolaryngol Clin North Am 1998; 21: 649-661.
13. Nederfors T. Xerostomia and hyposalivation. Adv Dent Res 2000; 14: 48-56.
14. Nederfors T. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonist. Swed Dent J Suppl 1996; 116: 1-70.
15. Sreebny LM. Xerostomia: diagnosis, management and clinical complications. In: Saliva and oral health. 2nd ed. Edgar WM, O’Mullane DM, ed itors. London: British Dental Association, 1996.
16. Helms JF, Dodds WJ, Pele LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984; 310, 284-8.
17. Namiot Z, Rourk RM, Piascik R, Hetzel DP, Sarosiek J, McCallum RW. Interrelationship between esophageal challenge with mechanical and chemical stimuli and salivary protective mechanisms. Am J Gastroenterol. 1994; 89, 581-7.
18. Gottrick B, Akerman S, Ericson D, Torstenson R, Tobin G. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res 2004; 83: 393-397.
19. Fregly MJ. Attenuation of pilocarpine-induced drinking by chronic treatment with estrogens. Proc Soc Exp Biol Med 1980; 164: 178-183.
20. Kounenis G, Voutsas D, Koutsoviti-Papadoopoulou M, Elezoglu V. Inhibition of acetylcholinesterase by the H2-receptor antagonist nizatidine. J Pharmacobiodynamics. 1988; 11: 767-71.
21. Adach K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther. 2002; 16: 297-301.
22. Schuurkes J. Facilitation of acetylcholine release via serotonin receptors: effect of cisapride? In: Heading RC, Wood JD, eds. Gastrointestinal Dysmotility. Focus on Cisapride. New York: Raven Press, 1992: 107-115.
23. Suzuki M, Miura S, Mor i M, K ai A, SuzukiH, Fukushima D, Suematsu M, Tsuchiya M. Rebetapride, a novel antilucretor agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375-1378.
24. akahashi T, Kurosawa S, Wiley J, Owyang C. Mechanism for the gastrokinetic action of dimperidone. In vitro studies in guinea pigs. Gastroenterology 1991; 101: 703-710.

Authors’ contributions: Yoshihisa Urita wrote the paper and contributed to acquiring data. Toshiyasu Watanabe, Tadashi Maeda, Yosuke Sasaki and Kazuo Hike contributed to analyzing data. Hiroshi Muto, Masaki Sanaka and Hitoshi Nakajima contributed to drafting the manuscript. Nagato Shimada and Mo tonobu Sugimoto contributed to enhancing its intellectual content.